You are invited to join us at the 2021 PSI Conference, being held online from 21 to 23 June 2021.
Registration for the conference is now open. Please click below for further information and to access the registration portal.
Sponsorship opportunities are available that include complimentary delegate passes. Such passes will be issued separately. If your organisation is a sponsor of the conference (or plans to sponsor the conference) please check with your colleagues to see if you have access to a complimentary place before registering on the conference portal. Details on conference sponsorship opportunities can be found below.
SPOTLIGHT ON: Poster Submissions
Only ONE week left to submit your poster abstract!
The deadline for abstracts for oral presentations has now passed and the Scientific Committee is in the process of reviewing the many high-quality submissions that we have received.
We are currently still accepting submissions for posters. There will be a dedicated area for posters within the conference platform allowing attendees to quickly and easily browse through all posters using a poster carousel. With good design and clear layout, posters are an excellent way of communicating a piece of work or topic. Don’t miss the opportunity to get involved in the conference. 

The deadline for poster presentations is 26th March 2021.
As is traditional with the PSI conference we are pleased to confirm that we have a session planned from the winner of the RSS/PSI award for statistics in the pharmaceutical industry, Sandeep Menon. Sandeep won the award for “Influential Quantitative Leadership in several domains in Early Clinical Development - creating a culture of quantitative decision making within a major pharmaceutical company.” Sandeep will present a session on the Application of Digital Medicine in Drug Development.
Sandeep Menon
Senior Vice President and Head of Early Clinical Development, Pfizer Inc
Artificial intelligence (AI) or machine learning (ML) has been used in drug discovery in biopharmaceutical companies for nearly 20 years. The clinical endpoints currently collected in the clinical practice and clinical trials are unable to give a holistic assessment of the patient prognosis and quality of life as it is usually collected at discrete timepoints and protocol pre-specified in-patient visits.  In addition, patients who are unable to come to the clinic physically miss their visits and have incomplete assessments. This was also apparent during the COVID-19 pandemic when patients were unable to get to the clinic. Digital endpoints collected through digital sensors have the potential to circumvent these situations and holistic measure the patient outcomes 24/7 and is the future of drug development. In this session, we will discuss some case studies where we have implemented digital sensors, its impact on some of the therapeutics areas, regulatory interactions, implementation challenges and opportunities to measure more robust clinical endpoints. We will also discuss role of quantitative scientists especially statisticians to lead in this new paradigm.
PROGRAMME HIGHLIGHT: Celebrating the positive impact Statisticians have had on the fight against COVID-19
Statisticians have been in the spotlight during the COVID-19 pandemic. The number of areas Statisticians have positively impacted will be championed in this session. Examples will be given of the amazing impact Statisticians have had on, for example, choice of endpoints to use in COVID-19 treatment trials, reducing timelines in vaccine developments and communicating key public health messages in a time of world crisis. After three talks focused on different aspects of Statisticians' work, the session will conclude with a panel discussion which will reflect on lessons learnt from the pandemic and highlight approaches that should be carried forward to accelerate drug development and improve the way complex clinical trial results are communicated in a post-pandemic world.

This session has been arranged by the COVID-19 and Vaccines Special Interest Groups, with presenters Ian Hirsch (AstraZeneca), Andrew Thomson (European Medicines Agency), Geert Molenberghs (Hasselt University and KU Leuven) and Kenneth Koury (Pfizer).
Let your colleagues know...

Please share this email with any colleagues and friends who you think will be interested in the PSI Annual Conference.
For any enquiries... .......

Should you require any assistance, please don't hesitate to contact the PSI conference secretariat.

Tel: +44 (0) 1730 715 235
A message from the Conference Chair...

With only three months to go, the Scientific Committee are getting very excited with the prospects of this year’s conference! Curious who we are? You can find out about the committee here.
Paul Terrill
Conference Chair
As part of the management and organization of events, MCI on behalf of PSI processes some of your personal data with your consent or as part of the execution of a contract. To learn more about your rights and our privacy practices: Privacy Policy. You received this email because you are subscribed to the mailing list of PSI, if you no longer wish to receive messages from us, please unsubscribe.

PSI | +44 (0) 1730 715 235 | |